Drug Trial Radar · NCT03295396
ONC201 in Adults With Recurrent H3 K27M-mutant Glioma
Last checked: Nov 19, 2026Latest source record: Jul 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
73
Actual
Start
Oct 30, 2017
Primary completion
Dec 31, 2022
Study completion Jul 19, 2023
Sponsor
- Lead sponsor
- Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
- Sponsor type
- Industry
- Collaborators
- Oncoceutics, Inc.
- First posted
- Sep 27, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was a Phase 2, open-label, 2-arm study of dordaviprone (ONC201) in patients with recurrent H3 K27M- mutant glioma. The primary assessment of dordaviprone (ONC201) involved evaluating its anti-tumor activity through the overall response rate according to the Response Assessment in Neuro-Oncology (RANO) criteria for high-grade glioma (HGG).
Conditions
- Glioma
Interventions
Dordaviprone (ONC201)Drug
Dordaviprone (ONC201) is a central nervous system (CNS)-penetrant, small-molecule imipridone that acts as a mitochondrial caseinolytic protease P (ClpP) agonist and a dopamine receptor D2 (DRD2) antagonist.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Patients With Overall ResponseTime frame: From first dose of study treatment through study completion, an average of 1 year
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
University of California, San Francisco
San Francisco, California
Stanford Cancer Center
Stanford, California
University of Michigan
Ann Arbor, Michigan
University of Minnesota
Minneapolis, Minnesota
New York University School of Medicine
New York, New York
Columbia University
New York, New York
Levine Cancer Institute
Charlotte, North Carolina
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania
MD Anderson Cancer Center
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.